Marson T. The SANAD II study of effectiveness of valproate or levetiracetam in generalised and unclassifiable epilepsy: an un-blinded randomised controlled trial. 5th European Academy of Neurology (EAN) Congress, abstract O4125.
Donanemab (Kisunla) krijgt marketingautorisatie van Europese Commissie voor vroeg-symptomatische Alzheimer
okt 2025 | Dementie